Immunotherapy Focus VBI Vaccines is actively pursuing immunology driven prevention and treatment across infectious diseases and aggressive cancers, presenting multiple cross-sell opportunities with partners in oncology and virology pipelines, and potential licensing or collaboration deals around their VLP and eVLP platforms.

Strategic Partnerships Recent and ongoing collaborations with Brii Biosciences and APAC commercialization via PreHevbri indicate a track record and appetite for strategic partnerships, suggesting BD outreach could target regional distributors, contract manufacturers, and co-development alliances in key markets.

Clinical Programs VBI is advancing Phase 2b data for VBI-1901 in recurrent glioblastoma and pursuing HBV therapies; there are opportunities to position VBI’s immunotherapy assets to specialty clinics, academic centers, and translational research partners seeking novel cancer vaccines or HBV interventions.

Global Footprint With headquarters in Cambridge and research sites in Ottawa and Rehovot, VBI presents geographic expansion potential. Sales could target regional biotech clusters, contract research services, and cross-border manufacturing collaborations to scale the eVLP platform and IVN technologies.

Financial Leverage Having substantial funding and a diversified portfolio (revenue in the low millions but large funding runway) creates a window for strategic co-development, milestone-driven deals, and early access agreements with pharmaceutical and biotechnology partners seeking risk-adjusted vaccine or immunotherapy programs.